Inhibitory effect of glycyrrhizin on NF-κB binding activity in CCl(4-) plus ethanol-induced liver cirrhosis in rats

Liver

Volumn 18, Issue 3, 1998, Pages 180-185

  Wang, Ji Yao ^a   Guo, Jin Sheng ^a   Li, Hai ^b   Liu, Shu Ling ^c   Zern, Mark A ^c  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cirrhosis; Glycyrrhizin; Liver injury; NF B; Potenlini

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ANTIFIBROTIC AGENT; CARBON TETRACHLORIDE; GLYCYRRHIZIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; POTENLINI; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG MECHANISM; EXPERIMENTAL LIVER CIRRHOSIS; FATTY LIVER; GLYCYRRHIZA; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER INJURY; LIVER TOXICITY; MALE; NONHUMAN; RAT;

EID: 0031845303     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0676.1998.tb00147.x     Document Type: Article

References (39)

1. NAGAI T, EGASHIRA T, YAMANAKA Y, KOHNO M. The protective effect of glycyrrhizin against injury of the liver caused by ischemia-reperfusion. Arch Environ Contam Toxic 1991; 20: 432-6.
2. NOSE M, ITO M, KAMIMURA K, SHIMIZU M, OGIHARA Y. A comparison of the antihepatotoxic activity between glycyrrhizin and glycyrrhetinic acid. Planta Med 1994; 60: 136-9.
3. SHIBAYAMA Y. Prevention of hepatotoxic responses to chemicals by glycyrrhizin in rats. Exp Mol Pathol 1989; 51: 48-55.
4. FUJISAWA K, WATANABE Y, KIMURA K. Therapeutic approach to chronic active hepatitis with glycyrrhizin. Asian Med J 1980; 23. 745-6.
5. SUZUKI H, OHZA Y, TAKINO T, FUJUSAWA K, HIRAYAMA C. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis - double blind trial. Asian Med J 1983; 23: 423-38.
6. ZHAO M Q, HAN D W, MA X H, ZHAO Y C, YIN L, Li C M. The preventive and therapeutic actions of glycyrrhizin, glycyrrhetic acid and crude saikosides on experimental cirrhosis in rats. Acta Pharm Sinica 1983; 18: 325-31.
7. WANG J Y, LIU H Y, HU D C, XIA D Q. A randomized controlled trial of potenlini on chronic active hepatitis B. Chin J Infectious Dis 1991; 9: 208-10.
8. WANG J Y, LIU W T, HU M Y, ZHU W N, TONG J Q. Inhibition of procollagen type I, III mRNA expressions of fibroblasts by glycyrrhizic acid. Chin J Dig 1997; 17: 60-1.
9. ARASE Y, IKEDA K, MURASHIMA N, et al. The long term efficacy of glvcyrrhizin in chronic hepatitis C patients. Cancer 1997; 79: 1494-1500.
10. TAKINO T. The effects of hepatotherapeutic drugs on chronic liver diseases evaluated by double blind trials in Japan. J Kyoto Prefect Univ Med 1984; 93: 689-703.
11. POMPEI R, FLORE O, MARCCIALIS M A, PANI A, LODDO B. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature 1979; 281: 689-90.
12. SHINADA M, AZUMA M, KAWAI H, et al. Enhancement of interferon-producuon in glycyrrhizin-treated human peripheral lymphocytes in response to concanavalin A and to surface antigen of hepatitis B virus. Proc Soc Exp Biol Med 1986; 181 205-10.
13. OHUCHI K, KAMADA Y, LEVINE L, TSURUFULI S. Glycyrrhizin inhibits prostaglandin E2 production by activated peritoneal macrophages from rats. Prostaglandins Med 1981; 7: 457-63.
14. OKIMASU E, MOROMIZATO Y, WATANABE S, et al. Inhibition of phospholipase A2 and platelet aggregation by glycyrrhizin, an antiinflammation drug. Acta Med Okayama 1983; 37: 385-91.
15. WHORWOOD C B, SHEPPARD M C, STEWART P M. Licorice inhibits 11-beta-hydroxysteroid dehydrogenase messenger ribonucleic acid level and potential glucocorticoid hormone action. Endocrinology 1993; 132: 2287-92.
16. MARANDICI A, MONDER C. Inhibition by glycyrrhetinic acid of rat tissue 11 beta-hydroxysteroid dehydrogenase in vivo. Steroids 1993; 58: 153-6.
17. AKAO T, TERASAWA T, HIAS S, KOBASHI K. Inhibitory effects of glycyrrhetic acid derivatives on 11-beta and 3-alpha hydroxysteroid dehydrogenases of rat liver. Chem Pharm Bull Tokyo 1992; 40: 3021-4.
18. WEBB T E, STROMBERG P C, ABOU ISSA H, CURLEY JR R W, MOSCHBERGER M. Effect of dietary soybean and licorice on the male F344 rat: an integrated study of some parameters relevant to cancer chemoprevention. Nutr Cancer 1992; 18: 215-330.
19. YAO T, DEGLI ESPOSTI S, HUANG L, ARNON R, SPANGENBERGER A, ZERN M A. Inhibition of carbon tetrachloride induced liver injury by liposomes containing vitamin E. Am J Physiol 1994; 267: G476-84.
20. 4-induced hepatic injury in mice is associated with inhibition of nuclear factor-kappa B binding. Hepatology 1995; 22: 1474-81.
21. YAMAMURA Y, SANTA T, KOTAKI H, UCHINO K, SAWADA Y, IGA T. Administration-route dependency of absorption of glycyrrhizin in rats: intraperitoneal administration dramatically enhanced bioavailability. Biol Pharm Bull 1995; 18: 337-41.
22. GORSKI K, CARNEIRO M, SCHIBLER R. Tissue specific in vitro transcription from the mouse albumin promoter. Cell 1986; 47: 767-76.
23. MIRZA A, LIU S L, FRIZELL E, et al. A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-κB. Am J Physiol 1997; 272: G281-8.
24. LIU J K, BERGMAN Y, ZARET K. The mouse albumin promoter and a distal upstream site are simultaneously DNase I hypersensitive in liver chromatin and bind similar liver-abundant factors in vivo. Gene Dev 1988; 2: 528-41.
25. RUWART M J, RUSH B D, SNYDER K F, PETERS K M, APPELMAN H D, HENLEY K S. 16,16-diethyl prostaglamine E2 delays collagen formation in nutritional injury in rat liver. Hepatology 1988; 8: 61-4.
26. ZHU J X, WANG B E, WANG T L. Study on the therapeutic effect of cordyceps mycelium on experimental hepatic fibrosis of rat. Chin J Dig 1994; 14: 333-5.
27. BALDWIN A S. The NF-κB proteins: new discoveries and insights. Ann Rev Immunol 1996; 14: 649-81.
28. MEYER M, CASELMANN W H, SCHLATER V, SCHRECK R, HOFSCHNEIDER P H. BAEUERLE P A. Hepatitis B virus transactivator MHBs: activation of NF-κB, selective inhibition by antioxidants and integral membrane localization. EMBO J 1992; 11: 2991-3001.
29. BAEUERLE P A, BALTIMORE D. NF-κB: ten years after. Cell 1996; 87: 13-20.
30. DEG A A, BALTIMORE D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996; 274: 782-4.
31. WANG C Y, MAYO M W, BALDWIN JR A S. TNF and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996; 274: 784-7.
32. ANTWERP D J V, MARTIN S J, KAFRI T, GREEN DR, WERMA IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996; 274: 787-9.
33. HELENIUS M, HONNINEN M, LEHTINEN S K, SALMINEN A. Changes associated with aging and replicate senescence in the regulation of transcription factor nuclear factor-κB. Biochem J 1996; 318: 603-8.
34. FREEDMAN A R, SHARMA RJ, NABEL G J, EMERSON S G, GRIFFIN G E. Cellular distribution of nuclear factor-κB binding activity in rat liver. Biochem J 1992; 287: 645-9.
35. CRESSMEN D E, GREENBAUM L E, HABER B A, TAUB R, Rapid activation of post-hepatectomy factor/nuclear factor-κB in hepatocytes, a primary response in the regenerating liver. J Biol Chem 1994; 269: 30429-35.
36. SCHEINMAN R I, COGSWELL P C, LOFQUIST A K, BALDWIN JR A S. Role of transcription activation of IκBa in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-6.
37. AUPHAN N, DIDONATO J A, ROSETTE C, HELMBERG A, KARIN M. Immunosuppression by glycocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995; 270: 286-90.
38. ISHIKAWA A, KANAMARU R, WAKUI A, KANNO S, OHTSUKI K. Characterization of glycyrrhizin-binding protein kinase from the crude membrane fraction of rat liver. Biochem Biophys Res Commun 1990; 167: 876-82.
39. ZHONG H H, YANG H S, BROMAGE H E, TEMPST P, GHOSH S. The transcription activity of NF-κB is regulated by the IκB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 1997; 89: 413-24.